

Patient Card

Please keep this card with you at all times while you are on treatment with Tolvaptan Teva and for one-week post-treatment.

This non-promotional material is intended for patients prescribed **Tolvaptan Teva**

TOL-GB-NP-00021
Version 3

Date of Preparation: January 2026
Date of MHRA Approval: February 2026

Patient Card

Present this card to any healthcare professional that you see, before any medical treatment or intervention.

Patient's name:

Date Tolvaptan Teva first prescribed:

Doctor's name:

Treatment centre's name:

Treatment centre's contact number:

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse.

This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via: the Yellow Card website www.mhra.gov.uk/yellowcard or the free Yellow Card app available from the "[Apple App Store](#)" or "[Google Play Store](#)".

Alternatively, you can report a suspected side effect to the Yellow Card scheme by calling 0800 731 6789 for free, Monday to Friday between 9am and 5pm. You can leave a message outside of these hours.

When reporting please provide as much information as possible.

By reporting side effects, you can help provide more information on the safety of this medicine. Side effects may also be reported to Teva UK Limited *via* email to **uk.safety@tevauk.com** or by calling **+44 (0) 207 540 7117**.

Important safety information for patients

Tolvaptan can cause your liver not to work properly.

Your doctor will arrange blood tests for liver function testing:

- Before starting treatment with Tolvaptan
- Monthly for the first 18 months of treatment
- Then every 3 months thereafter

Inform your doctor immediately if you experience any of these signs that could indicate potential liver problems:

- Tiredness
- Loss of appetite
- Pain in the abdomen
- Dark urine
- Yellowing of skin or eyes (jaundice)
- Nausea
- Vomiting
- Fever
- Itching of your skin
- Flu-like syndrome (joint and muscle pain with fever)

Tolvaptan can cause dehydration/severe dehydration.

Tolvaptan can increase your urine production which may result in excessive water loss and dehydration.

Drink plenty of fluids to avoid dehydration and consult your doctor if you are unable to drink or if you experience any of these the following symptoms.

Symptoms of dehydration may include:

- Increased thirst
- Dark yellow, strong-smelling urine
- Feeling tired or sleepy
- Dizziness
- Decreased urination
- Dry mouth
- Sunken eyes

If dehydration is left untreated, it can become severe.

Severe dehydration is a medical emergency and requires immediate medical attention.

Symptoms can include unusual tiredness, confusion, dizziness, not urinated all day.

If you experience any of these symptoms, contact your doctor, call 111 or go to A&E immediately to seek medical advice.¹

¹ NHS dehydration – available at <https://www.nhs.uk/conditions/Dehydration/> (last accessed September 2025).

Important safety information for HCPs

Tolvaptan blocks the action of vasopressin in the kidney.

This can result in an increase in urination which may lead to severe dehydration or excessive water loss. Symptoms of dehydration may include increased thirst, dry mouth, feeling tired or sleepy, decreased urination, headache, dry skin, dizziness, rapid heart rate, confusion and poor skin elasticity.

Tolvaptan can cause liver injury.

Blood tests for liver function testing must be performed periodically (monthly for the first 18 months, then every 3 months thereafter).

Therapy should be interrupted or discontinued if significant increase of liver enzymes and/or clinical symptoms of liver injury persist.

For more information please contact Teva UK Limited Scientific Services at **medinfo@tevauk.com** or call **0207 540 7117**

Teva UK Limited, Ridings Point, Whistler Dr, Castleford WF10 5HX

TOL-GB-NP-00021

Version 3

Date of Preparation: January 2026

Date of MHRA Approval: February 2026